Press Releases
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo...
Aegis Subsidiary HyprC Joins Forces with McMaster in Multi-Million Dollar Push to Redefine Critical Energy Storage - Targeting High-Growth Markets in Ports, AI Data Centres and Hybrid Nuclear Energy Systems; C$1 Million Corporate Investment Expected to Leverage Significant Research Grants
Hamilton, Ontario--(Newsfile Corp. - June 15, 2026) - HyprC Systems Inc. ("HyprC"), a subsidiary of Aegis Critical Energy Defence Corp (CSE: QESS) (OTCQB: QESSF) (FSE: JG6) ("Aegis" or the "Company"), today announced the launch of its next-generation high-C-rate battery platform, designed for the world's most demanding power applications in ports, AI data centres and hybrid nuclear energy systems. The launch is supported by a targeted multi-year investment program and a major research collaboration with McMaster University, to be led by Professor Saeid Habibi, a recognised leader in advanced control systems, fault diagnostics and battery energy storage research...
Truecaller's Board of Directors has resolved to resume the repurchase of shares
STOCKHOLM, June 15, 2026 /PRNewswire/ -- The Board of Truecaller has resolved to utilize the mandate adopted by the Annual General Meeting on the 22nd of May 2026 to buy back B-shares. The purpose of the buybacks is to give the board of directors the opportunity to continuously adapt the company's capital structure and thereby contribute to increased shareholder value, to be able to exploit attractive acquisition opportunities by fully or partly financing future acquisitions of companies, with the company's own shares...
InterDigital to Spotlight Innovation Underpinning Interactive AR and Energy-Efficient Video Streaming at 2026 FOKUS Media Web Symposium
WILMINGTON, Del., June 15, 2026 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a wireless, video, and AI technology research and development company, will participate in the 13th FOKUS Media Web Symposium to demonstrate expertise and the latest innovations enabling interactive AR experiences and energy-efficient video streaming...
Willis unveils new technology to counter existential risk to property insurance from climate change volatility
LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Willis, a WTW business (NASDAQ: WTW), today unveiled a new version of its Climate Diagnostic model to help risk managers better understand and respond to climate-driven volatility affecting property insurance markets. Embedded within WTW's Risk IQ platform, Climate Diagnostic is a climate risk technology capable of predicting the current and future impact of floods, windstorms and other material climate threats on an organisation's assets, business activities and supply chain...
Survey: Nearly All European Organisations Feel Pressure to Scale AI for Customer Experience, Yet Only 38% Have a Clear Approach to Governance
NOTTINGHAM, England--(BUSINESS WIRE)--New research from CallMiner, the global leader in customer experience (CX) automation powered by conversation intelligence, reveals that organisations across Europe are rapidly scaling AI in CX, but governance frameworks are struggling to keep pace. While nearly all organisations (99%) say they are under pressure to scale AI in CX, fewer than four in ten (38%) say they have a clear and well-defined AI governance approach, creating growing risks across CX, g...
Northern Trust Receives Approval for New EU Banking Branch in Ireland
DUBLIN--(BUSINESS WIRE)--Northern Trust announced today that it has received a licence from the Central Bank of Ireland for the establishment of The Northern Trust Company, Ireland Branch (Ireland Branch). This new banking branch will provide a range of custodial, banking and capital markets services, including domestically regulated banking services for Ireland-domiciled clients. Its activities will complement those of Northern Trust Global Services S.E., Northern Trust's continental European...
Eagle Plains' Partner Xcite Uranium Receives Permits and Commences Fieldwork at the Uranium City Project, Saskatchewan
CRANBROOK, BC / ACCESS Newswire / June 15, 2026 / Eagle Plains Resources Ltd. (TSX-V:EPL)(OTCQB:EGPLF) ("EPL" or "Eagle Plains") is pleased to announce that partner Xcite Uranium Inc. (TSX-V:XRI) ("XRI or Xcite"), has approved the 2026 exploration plan and mobilized exploration crews to commence fieldwork at Eagle Plains' Uranium City Projects (the "Uranium City Projects"), northern Saskatchewan...
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
VANCOUVER, BC / ACCESS Newswire / June 15, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has commenced work with a Business Development & Licensing ("BD&L") specialist advisor to support the commercialization and partnering strategy for BNT23001, the Company's patented proprietary sublingual Cladribine orally dissolvable film ("ODF") formulation for the treatment of multiple sclerosis ("MS"). BNT23001 is designed as a differentiated alternative to conventional tablet-based Cladribine therapy, including Mavenclad, by offering a thin, dissolvable film placed under the tongue...
The Knot Worldwide Announces Integration with Venmo to Deliver Seamless Gifting Experiences for Couples and Guests
NEW YORK--(BUSINESS WIRE)--Today, The Knot Worldwide (TKWW), a leading global wedding technology platform and marketplace, announced Venmo, a money movement app for the next generation, is now a payment option within The Knot's Wedding Registry. This provides a free and trusted way for users to send money from their bank, debit card, or Venmo balance for registry cash fund gifting. The new offering gives wedding guests a familiar and trusted way to contribute to couples' cash funds, while also...
N-able Opens Bengaluru Office to Accelerate Security Innovation and Talent Growth
BURLINGTON, Mass.--(BUSINESS WIRE)--N-able, Inc. (NYSE: NABL), a global cybersecurity company delivering business resilience, today announced the opening of its new Global Capability Centre (GCC) in Bengaluru, marking a strategic investment in India as the company expands its global security footprint in one of the world's fastest-growing cybersecurity markets.Reuters recently reported that India's GCC workforce is expected to reach 2.36 million employees by the end of 2026, with cybersecurity a...
Amundi, CACEIS and Ant International Collaborate to Advance Blockchain-Powered Treasury and Tokenised Investment Solutions
PARIS & SINGAPORE--(BUSINESS WIRE)--Amundi, the largest European asset manager, CACEIS, the European leader in asset servicing, and Ant International, a leading global digital payment, digitisation and financial technology company today announced milestones in their collaboration. Amundi has successfully launched tokenised share classes for the Amundi Money Market Fund – Short Term. Denominated in euro and US dollars, these bespoke tokenised share classes were developed for Ant International fo...
Alm. Brand A/S mandates Tier 2 Capital Notes transaction
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL
Alm. Brand A/S - Announces invitation to holders of its outstanding DKK 900 million Tier 2 Capital Notes to tender any and all notes for repurchase
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL
E3 Lithium Successfully Commissions Phase 2 of its Demonstration Facility
CALGARY, Alberta--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), “E3”, “E3 Lithium” or the “Company,” a leader in Canadian lithium development, has successfully commissioned Phase 2 of its Clearwater Project Demonstration Facility (the “Demo Facility”) and continues to operate the reservoir production test. Lithium analysis of the brine produced from the production test confirmed 75.8 mg/L lithium, demonstrating the continued consistency of the brine chemistry across th...
Edge Total Intelligence to Expand its U.S. Navy Presence: with U$1.2 Million Austal USA Contracts
Austal USA's Digital Secure Exchange for Additive Platform ("Digital SEA") is intended to provide U.S. Navy a secure platform and marketplace to enable trusted additive manufacturing data exchange, supplier collaboration, traceability, and production workflow visibility. edgeTI's edgeCore™ digital twin solution is contracted to serve as the secure integration and data brokerage layer for Digital SEA, unifying fragmented systems, data, users, and workflows into a real-time Single Point of Control (SPoC)...
Prospect Markets Engages Independent Trading Group as Market Maker
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2026) - Prospect Prediction Markets Inc. (TSXV: MKT) (OTCQB: MKTSF) (FSE: DEP) ("Prospect Markets" or the "Company") announces that it has engaged the services of Independent Trading Group ("ITG") to provide market-making services in accordance with TSX Venture Exchange ("TSXV") policies. ITG will trade shares of the Company on the TSXV and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares...
Clarivate's IPfolio Selected by Mitsubishi Fuso
Managing intellectual property more efficiently with leading data and expertise LONDON, June 15, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Mitsubishi Fuso Truck and Bus Corporation has selected IPfolio as its intellectual property (IP) management solution. IPfolio provides Mitsubishi Fuso with a modern, scalable foundation for IP management, bringing together trusted data, expert support, and integrated services in a single platform...
Red Cat Introduces Hellcat™, a Global Small UAS Configuration Built on the Proven Black Widow™ Platform
SALT LAKE CITY, June 15, 2026 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, today introduced Hellcat™, a dual-use small unmanned aircraft system (sUAS) built on the proven Black Widow™ platform and designed for rapidly evolving operational environments...
Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer. HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally...
Share buybacks in Ericsson during the period June 8 - June 12, 2026
STOCKHOLM, June 15, 2026 /PRNewswire/ -- During the period June 8 - June 12, 2026, Telefonaktiebolaget LM Ericsson (publ) ("Ericsson") (LEI code 549300W9JLPW15XIFM52) repurchased own Class B shares (ISIN: SE0000108656) as follows: Date Aggregated daily volume(number of shares) Weighted average shareprice per day (SEK) Total daily transactionvalue (SEK) 08/06/2026 400,000 119.0155 47,606,200.00 09/06/2026 600,000 114.7100 68,826,000.00 10/06/2026 600,000 111.8550 67,113,000.00 11/06/2026 600,000 112.9224 67,753,440.00 12/06/2026 500,000 115.1731 57,586,550.00 Total 2,700,000 114.4019 308,885,190.00 The share repurchases are a part of the share buyback program of up to SEK 15,000,000,000 which Ericsson announced on April 16, 2026, and which runs between April 23, 2026, and March 31, 2027, at the latest. The Board of Directors intends to propose to the 2027 Annual General Meeting that the repurchased shares, other than those used to fulfil Ericsson's obligations under its share-related incentive programs, are cancelled...
Completion of Option Agreements and Cleansing Notice
TORONTO and PERTH, Western Australia, June 15, 2026 (GLOBE NEWSWIRE) -- Cygnus Metals Limited (ASX: CY5; TSXV: CYG; OTCQB: CYGGF) (“Cygnus” or the “Company”) advises that it has today issued 3,000,000 fully paid ordinary shares on conversion of an equivalent number of vested performance rights and a total of 1,050,000 fully paid ordinary shares to the vendors under the respective option agreements for the Sakami Project and Beryl Lake property (which forms part of the Auclair Project), following shareholder approvals received at the Annual General Meeting on 1 May 2026 (together, the “Shares”)...
Sivers Semiconductors Withdraws Items From the Agenda of the 2026 Annual General Meeting
KISTA, Sweden, June 15, 2026 /PRNewswire/ -- The Board of Directors of Sivers Semiconductors AB (the "Company") has today, on 15 June 2026, resolved to withdraw items 14-16, set out in the notice to attend the Annual General Meeting 2026 to be held on 15 June 2026. The items have been withdrawn to allow the new Board of Directors to be elected at the Annual General Meeting to provide input on and review the employee incentive program...
Quickwork Launches Fully Self-Managed Integration Infrastructure for the AI Era
Quickwork's new on-premises, virtual private cloud (VPC), and air-gapped deployment capabilities enable enterprises to run integration, automation, and AI workflows entirely within their own controlled infrastructure environments. Quickwork's new on-premises, virtual private cloud (VPC), and air-gapped deployment capabilities enable enterprises to run integration, automation, and AI workflows entirely within their own controlled infrastructure environments...
ING appoints Hilde Garssen to the Management Board Banking
ING appoints Hilde Garssen to the Management Board Banking ING announced today that Hilde Garssen will be appointed to the Management Board Banking (MBB) as chief human resources officer (CHRO), effective 1 September 2026. Hilde is currently chief people officer and a member of the Board of Management at KPN...
Magnera Announces the Sale of Its Caerphilly, United Kingdom Operations
CHARLOTTE, North Carolina, June 15, 2026 (GLOBE NEWSWIRE) -- Magnera Corporation (NYSE: MAGN) today announced the sale of its Caerphilly, UK operations to Polyart Group, a Prudentia Capital holding.
BW Offshore: Company presentation
Company presentation BW Offshore is presenting at the BW Group Investor Meeting today. Please see the attached presentation.
SWI Group Expands Transatlantic Digital Infrastructure Platform with closing of $500 Million USD Acquisition of significant shareholding in a 1.3 GW USA portfolio
The acquisition secures significant shareholding in one of the largest privately held U.S. digital infrastructure platforms. SWI Group to reposition assets for high-performance computing and AI workloads, expanding the Group's combined global capacity to 3.6 GW.
VAALCO Energy, Inc. Announces Exciting Operational Update in Offshore Gabon and in Egypt
HOUSTON, June 15, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced positive operational updates offshore Gabon regarding the ongoing drilling program, including impressive initial well results on the Ebouri-5H well and mobilization of the rig to the SEENT platform. Additionally, the Company provided a positive update on the first well completed in the 2026 onshore Egypt drilling program...
Pulsar Helium Announces Expanded Land Position at Topaz, and Provides a Project Technical Update
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS...
IQE and Tower Semiconductor Announce Multi-year InP epiwafer Supply Agreement
CARDIFF, UK, and MIGDAL HAEMEK, Israel, June 15 2026 - IQE plc (AIM: IQE, "IQE" or the "Group"), the leading global supplier of compound semiconductor wafer products and advanced material solutions, and Tower Semiconductor (NASDAQ/TASE: TSEM), the leading foundry for high-value analog semiconductor solutions, are pleased to announce a multi-year agreement for the supply of Indium Phosphide (InP) epiwafers for optical connectivity solutions serving AI-driven data centre infrastructure...
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 15
Purchase of own shares LONDON, UK / ACCESS Newswire / June 15, 2026 / The Company announces that on 12 June 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026...
SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS
SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS June 15, 2026 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the first quarter 2026 interim dividend, which was announced on May 7, 2026 at US$0.3906 per ordinary share. Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling...
Novatus Global Appoints Andrew Pinnington as Chief Customer Officer
LONDON--(BUSINESS WIRE)--Novatus Global Limited (“Novatus” or “the Company”), an award-winning provider of regulatory technology solutions and consulting services to global financial institutions, today announced the appointment of Andrew Pinnington as Chief Customer Officer (CCO). This strategic hire reflects the Company's continued momentum following its $40 million growth investment from Silversmith Capital Partners in 2024 and signals Novatus's commitment to placing customer relationships a...
Electro Optic Systems to Establish European C2 AI Hub in France
PARIS & CANBERRA, Australia--(BUSINESS WIRE)--Electro Optic Systems (EOS) (ASX: EOS) today confirmed an investment of more than €10 million to establish France as its European hub for AI-enabled counter-drone command and control (“C2”) systems. The hub will be anchored by the headquarters of MARSS, the AI-enabled command-and-control specialist recently acquired by EOS, and will be located in Nice. The investment is expected to create up to 150 jobs over three years, including high value-added e...
SWI Group takes majority position in GDA, a 1.3 GW USA digital infrastructure group, taking SWI Group to a majority shareholding position.
The acquisition will increase SWI Group's shareholding in one of the largest privately held U.S. digital infrastructure platforms to majority holding position. SWI Group will work closely with management to reposition GDA's assets for high-performance computing and AI workloads, expanding the Group's combined global capacity to over 3.6 GW...
Caledonia Mining Corporation Plc: Publication of 2025 ESG Report
(NYSE American:CMCL)(AIM:CMCL)(VFEX:CMCL) SAINT HELIER, JE / ACCESS Newswire / June 15, 2026 / Caledonia Mining Corporation Plc ("Caledonia" or "the Company") announces the publication of its 2025 ESG Report. The full report is available on the Company's website at www.caledoniamining.com/esg/esg-reports...
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD) Urinary free cortisol (UFC) normalization is a clinically relevant measure in CD, where chronic cortisol excess is a key driver of morbidity, mortality and quality-of-life burden Preliminary Phase II Part A data showed UFC normalization in most evaluable adults with CD who completed individualized intravenous dose titration with asedebart1 VALBY, Denmark, June 15, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced preliminary Phase II Part A data from its ongoing study evaluating asedebart (Lu AG13909), an anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, in adults with Cushing's disease (CD)...
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabi...
WORLDLINE : Completion of reverse share split - Press release
Worldline announces the completion of its reverse share split Adjustment of the conversion/exchange ratio of the OCEANEs, the exercise parity of the Options, and the allocation rights of the Performance Shares and Free Shares Paris, La Défense, 15 June 2026 – Worldline S.A. [ISIN: FR0011981968 – Euronext: WLN] (the “Company” or “Worldline”), a European leader in payment services, announces today the completion of the reverse share split of the shares comprising its share capital, decided by Worldline's Board of Directors at its meeting held on 28 April 2026 in accordance with the tenth resolution approved by Worldline's shareholders at the general meeting held on 8 January 2026 (the “Shareholders' Meeting”), through the exchange of forty (40) existing shares with a par value of two euro cents (€0.02) each (the “Existing Shares”) for one (1) new share with a par value of eighty euro cents (€0.80) (a “New Share”)...
Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany
Dublin, Ireland and Heppenheim, Germany--(Newsfile Corp. - June 15, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the launch of its innovative acne cream Winlevi (clascoterone 1% cream) in Austria and Germany by its commercial partner InfectoPharm Arzneimittel und Consilium GmbH (“InfectoPharm”)...
Dassault Systèmes successfully issues €1 billion in bonds and refinances its revolving credit facility
Press Release VELIZY-VILLACOUBLAY, France — June 15, 2026 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION TO ANY U.S. PERSON OR INTO CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS PRESS RELEASE. Dassault Systèmes successfully issues €1 billion in bonds and refinances its revolving credit facility Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), rated A (stable) by S&P Global Ratings, announces the successful issuance of a bond which has been significantly oversubscribed by institutional investors...
Questerre successfully tests HCCO® Technology in a Commercial-Sized Vessel at PX Energy
THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone
PARIS--(BUSINESS WIRE)--Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and...
Defiance Launches SPCU, Delivering 2X Long Exposure to SpaceX in Its First Full Week of Trading
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long SpaceX ETF (Cboe: SPCU) . SPCU begins trading today at 4am ET and seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of SpaceX Class A common stock (NASDAQ: SPCX)...
Sky Aircraft Maintenance Named Authorized Garmin Aviation Dealer
New Garmin dealership expands avionics modernization capabilities for private and business aircraft operators New Garmin dealership expands avionics modernization capabilities for private and business aircraft operators
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on the FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch Happening at Its Los Angeles HQ on June 16
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF. “Welcome to issue #59 of the Weekly Report. Today, I want to give everyone a preview of the first launch event of FF's Full-Form EAI Robotics Universe Launch Season, which will take place in just two days. At 5:00 p.m. Pacific...
CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster presentations for CT0596 (an allogeneic CAR T-cell product targeting BCMA), and CT1190B (an allogeneic CAR T-cell product targeting CD19/CD20) at the 2026 Annual Congress of the European Hematology Association ("EHA"). Data for CT0596 in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia Eight patients, including 6 relapsed/refractory multiple myeloma (R/RMM) and 2 relapsed/refractory primary plasma cell leukemia (R/R pPCL), received CT0596 at the 4.5×10⁸ CAR⁺ T cell dose level...
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this case The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 14, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation...
Perseus Mining Increases Share Buy-Back from AUD100M to AUD 150M
Perth, June 15, 2026 (GLOBE NEWSWIRE) -- PERSEUS INCREASES ON-MARKET SHARE BUY-BACK TO A$150MILLION Perth, Western Australia/June 15, 2026/Perseus Mining Limited (ASX/TSX: PRU) is pleased to announce that on June 12, 2026, we have reached A$100 million of the A$100 million on-market share buyback announced in August 2025. Under this buyback, Perseus has purchased 19,077,751 shares at an average price of A$5.24 per share, of shares on issue at notification of the buyback on the 25 November 2025...
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026...
ComEd Reaches 99% Restoration Following Multi-Day Severe Storm Event
CHICAGO--(BUSINESS WIRE)--ComEd crews have nearly completed the restoration of power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With 99% of affected customers now restored, crews are in the final stages of repairs and remain committed to completing service restoration for all remaining customers. Multiple bands of severe weather moved through ComEd's northern Illinois service territory on Wednesday and Thursday,...
CEL-SCI Corporation Announces Pricing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026...
Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate
Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's and Québec's objectives for domestic processing of critical minerals MONTREAL, June 14, 2026 /PRNewswire/ – June 15, 2026 – Sydney, Australia Highlights Concept study completed evaluating future potential to process spodumene concentrate into a value-added lithium product, directly at the Shaakichiuwaanaan site. Following a structured review of seven processing flowsheet options to produce a "value added" lithium product, the study identified Primero's (NRW Holdings (ASX: NWH) subsidiary "Primero") proprietary ALi atmospheric leach process as the preferred value-added pathway for further study, given: its overall economic potential, strong logistics efficiency benefits and technical risk profile, and its alignment with the Company's sustainability objectives through practicing environmental care in processing and minimizing the Project's environmental footprint...
Oshkosh Defense Highlights Proven, Adaptable Tactical Mobility Solutions for Europe at Eurosatory 2026
PARIS--(BUSINESS WIRE)--As European and allied forces accelerate modernization efforts in response to evolving operational threats, Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK] business, will showcase proven tactical mobility solutions at Eurosatory 2026 designed to support interoperability, distributed operations and future battlefield requirements, without the risk and long development timelines of entirely new vehicle programs. For decades, Oshkosh Defense has supported allied mil...
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase 1b/2a ACTH-dependent Cushing's syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower dose SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented data today from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing's syndrome. The findings were included in an oral presentation titled “Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses with Sustained Androgen Reduction in Adults with Congenital Adrenal Hyperplasia” at Endocrine Society's Annual Meeting, ENDO 2026...
OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026
MENLO PARK, Calif.--(BUSINESS WIRE)-- #ClinicalData--OrsoBio presents positive Phase 2a data for its LXR inverse agonist TLC-2716 in SHTG and MASLD at ENDO 2026.
Elektros Inc. Advances Its Lithium and EV Innovation Strategy as Global Electrification Momentum Accelerates
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
Elektros Inc. Strengthens Its Position in Lithium and EV Innovation as the Global Electrification Era Gains Momentum
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
Elektros Inc. Highlights Long-Term Lithium and EV Innovation Strategy as Global Investors Focus on the Future of Electrification
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
Elektros Inc. Embraces the Bright Future of Lithium and EV Innovation as Its Global Electrification Mission Continues to Advance
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
AV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal
OSTFILDERN, Germany--(BUSINESS WIRE)---- $AVAV #AVAV--AeroVironment, Inc. (“AV”), a global leader in autonomous systems, today announced the launch of TOM 50 RE, a compact, backpackable uncrewed ground vehicle (UGV) developed by its wholly owned subsidiary Telerob. Designed for mobile exploration, mission-accompanying reconnaissance, explosive threat disposal, and operational support, TOM 50 RE enables dismounted forces, explosive ordnance disposal (EOD) teams, and special operations units—including SWAT—to ra...
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab's potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU...
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –
Tradr to Ring Opening Bell at Cboe to Celebrate SpaceX ETF Launches
Tradr ETFs will ring Cboe's Opening Bell on June 15 to celebrate the launch of SPCM and SPCG, ETFs providing 200% leveraged long and short exposure to the newly public SpaceX stock. Firm to commemorate the launch of SPCM and SPCG from the center of the world's largest options trading floor NEW YORK, June 14, 2026 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced that its team will ring the Opening Bell at Cboe Global Markets at 8:30 am on Monday, June 15, 2026...
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP...
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
GENEVA--(BUSINESS WIRE)--OM Pharma Unveils the Largest Multi-Country Real-World Evidence Study on Broncho Vaxom (OM 85) for RTI Prevention at EAACI 2026.
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
INDIANAPOLIS, June 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study met its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS), demonstrating that the addition of pirtobrutinib to a two-year venetoclax plus rituximab regimen reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001)...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006)...
Elektros Inc. Ignites New Momentum Across Lithium, EV Innovation, and Critical Minerals as the Global Electrification Era Accelerates
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update regarding its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and strategic initiatives supporting the future of transportation, energy infrastructure, and critical minerals...
Elektros Inc. Powers Ahead as Global Demand for Lithium, EV Innovation, and Critical Minerals Creates New Opportunities for Electrification
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update regarding its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and strategic initiatives supporting the future of transportation, energy infrastructure, and critical minerals...
Elektros Inc. Accelerates Its Vision for Lithium, EV Innovation, and the Future of Electrification
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
ICE Box Claims Evaluated: Personal Document Storage System for Organization & Secure Protection in Case of Emergencies
ICE Box organizes vital records, estate planning documents, and emergency files in one fireproof box with a 32GB USB stick and expert-developed checklist.
Powering the Future of Electrification
Elektros Inc. Continues Advancing Lithium Opportunities, EV Charging Innovation, and Strategic Growth Initiatives Positioned to Capitalize on Expanding Global Demand for Critical Minerals, Energy Infrastructure, and Electric Vehicles ELEKTROS INC. (OTC PINK:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC PINK:ELEK) today provided an update regarding its ongoing focus on hard rock lithium opportunities, patented electric vehicle charging technology, and continued efforts to advance its long-term strategic initiatives in support of the evolving electrification marketplace...
XM Announces Enhanced Trading Conditions and Opportunities for Global Traders - Featuring Partner Code 274PQ
TORONTO, June 14, 2026 (GLOBE NEWSWIRE) -- As participation in online financial markets continues to expand worldwide, trading platforms are increasingly focused on technology, education, and user accessibility. XM, an international online trading platform, has announced ongoing developments across its platform ecosystem while highlighting the availability of Partner Code 274PQ for eligible new users during the registration process...
Air Canada and the IAMAW Reach Tentative Agreement on New Contract
MONTRÉAL, June 13, 2026 (GLOBE NEWSWIRE) -- Air Canada today said it has reached a tentative collective agreement with the International Association of Machinists and Aerospace Workers (IAMAW) representing more than 11,000 Air Canada employees in Maintenance, Cabin Services, Airport Airside Operations, Cargo, Finance and Clerical...
Cycclone, Inc. Announces Agreement in Principle for the Acquisition of AI Robotics Company
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2026 / Cycclone, Inc. (OTCID:CYCL) today acknowledges reaching an agreement in principle to acquire an AI Robotics design, develop and manufacturing company under the newly formed division, Cycclone Ai Robotics. Recently an agreement in principle has been reached for Cycclone to acquire an American AI Robotics company based in California...
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium...
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% wi...
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. This first-in-class type II JAK2 inhibitor was designed to selectively bind the type II conformation of the JAK2 kinase in order to potentially provide greater efficacy than existing therapies and a novel treatment option for patients who become resistant to type I JAK2 inhibitors...
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET.
AI Infrastructure News: How Investors Can Participate in the Cloud GPU Leasing Boom and Generate Passive Income in 2026
AI GPU Rental is offering short-term ways to invest in AI computing power. New users can also get up to $128 in free credits to try it. AI GPU Rental is offering short-term ways to invest in AI computing power. New users can also get up to $128 in free credits to try it.
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden compared with placebo Patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes Mitapivat was well-tolerated, with a safety profile consistent with previous trials of mitapivat in sickle cell disease Company to host investor conference call and webcast today at 9:00 a.m. ET (3:00 p.m...